Pittsburgh, PA, United States of America

George T Topalov

This inventor holds 31 USPTO granted patents and 6 published patent applications, plus 5 CIPO patents and 8 EPO patents, primarily in Kv7 Channel Activators. Top assignees: Array Biopharma Inc., Knopp Biosciences, LLC, Biohaven Therapeutics Ltd.. Active years: 2008-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: George T Topalov. Retrieved from https://idiyas.com/inventor/george-t-topalov

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 31 (Patent Applications = 6)

% Patents Active = 64.5

CIPO Patents = 5 (Patent Applications = 2)

EPO Patents = 8 (Patent Applications = 10)

Average Co-Inventor Count = 7.5

ph-index = 8

Forward Citations = 140(Granted Patents)

Location History:

Boulder, CO (US) (2013 - 2015)
Pittsburg, PA (US) (2015)
Superior, CO (US) (2008 - 2017)
Pittsburgh, PA (US) (2014 - 2023)

Company Filing History:

Knopp Biosciences, LLC

patents

4 out of 32

Biohaven Therapeutics Ltd.

where one patent can have more than one assignee

Years Active: 2008-2025

Loading Chart...

Areas of Expertise:

Kv7 Channel Activators

Receptor Tyrosine Kinase Inhibitors

Quinazoline Analogs

Imidazo[4,5-b]pyridin-2-yl Amides

Benzoimidazol-1,2-yl Amides

Type III Inhibitors

PIM Kinase Inhibitors

mTOR Inhibitors

cFMS Inhibitors

RAF Inhibitors

Triazolopyridine Compounds

Substituted Pyrazolo[1,5-a]pyrimidine Compounds

31 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12351559 - Benzoimidazol benzomidazol-1,2-yl amides as Kv7 channel activators (2025-07-08),

2. 12286408 - KV7 channel activators compositions and methods of use (2025-04-29),

3. 11834418 - Benzoimidazol-1,2-yl amides as Kv7 channel activators (2023-12-05),

4. 11724990 - Kv7 channel activators compositions and methods of use (2023-08-15),

5. 11261162 - KV7 channel activators compositions and methods of use (2022-03-01),

6. 11174273 - Quinazoline analogs as receptor tyrosine kinase inhibitors (2021-11-16),

7. 10906877 - Benzoimidazol-1,2-yl amides as Kv7 channel activators (2021-02-02),

8. 10851067 - Kv7 channel activators compositions and methods of use (2020-12-01),

9. 10669269 - Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors (2020-06-02),

10. 10526328 - Imidazo[4,5-b]pyridin-2-yl amides as Kv7 channel activators (2020-01-07),

11. 10385025 - Benzoimidazol-1,2-yl amides as Kv7 channel activators (2019-08-20),

12. 10221194 - Quinazoline analogs as receptor tyrosine kinase inhibitors (2019-03-05),

13. 10106536 - Imidazo(4,5-B) pyridin-2-yl amides as KV7 channel activators (2018-10-23),

14. 9914708 - Benzoimidazol-1,2-yl amides as Kv7 channel activators (2018-03-13),

15. 9809590 - Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors (2017-11-07),

Title: George T Topalov: Pioneering Innovations in Pharmaceutical Research

Introduction: George T Topalov, a prolific inventor based in Pittsburgh, PA (US), has made significant contributions to the field of pharmaceutical research. With an impressive portfolio of 29 patents, Topalov is recognized for his groundbreaking work in developing compounds for treating various disorders associated with Kv7 potassium channel activators.

Latest Patents: Among his latest patents is "Benzoimidazol-1,2-yl amides as Kv7 channel activators", which highlights the use of optionally substituted benzoimidazol-1,2-yl amides in treating Kv7 associated diseases. Another notable patent is "Kv7 channel activators compositions and methods of use", which focuses on pharmaceutical compositions comprising these compounds for the treatment of conditions such as epilepsy, ALS, pain, and hyperexcitability.

Career Highlights: Topalov has gained experience and expertise through his work with reputable companies in the pharmaceutical industry. He has significantly contributed to research projects at Array Biopharma Inc. and Knopp Biosciences, LLC, showcasing his dedication to advancing drug discovery and development.

Collaborations: Throughout his career, Topalov has collaborated with accomplished individuals in the field of pharmaceutical research. Some of his notable coworkers include Qian Zhao and David A Mareska, who have worked alongside him on innovative projects aimed at improving treatment options for various disorders.

Conclusion: George T Topalov's relentless pursuit of innovation and his remarkable ability to develop novel compounds for therapeutic purposes have solidified his reputation as a leading figure in the pharmaceutical research landscape. His groundbreaking patents and collaborations with industry experts underscore his commitment to advancing the field and making a positive impact on global healthcare.

Profile summary based on public USPTO records.